Obviously, a high percentage of ER expression in male breast carcinoma is inevitably associated with the rarity of HER2+/ER- subtype carcinoma, which reportedly has a worse prognosis than that of luminal B tumors (HER2+/ER+ or PR+) in female patients. The gene discussed is ERBB2; the disease is carcinoma.